These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3137597)

  • 1. Characterization of the scopolamine stimulus in rats.
    Jung M; Perio A; Worms P; Biziere K
    Psychopharmacology (Berl); 1988; 95(2):195-9. PubMed ID: 3137597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of the physostigmine stimulus in rats.
    Jung M; Perio A; Worms P; Soubrie P
    Psychopharmacology (Berl); 1988; 95(4):553-5. PubMed ID: 3145526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinergic mediation of the discriminative stimulus properties of clozapine.
    Nielsen EB
    Psychopharmacology (Berl); 1988; 94(1):115-8. PubMed ID: 3126519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminative stimulus properties of physostigmine in rats.
    Tang AH; Franklin SR
    Eur J Pharmacol; 1988 Aug; 153(1):97-104. PubMed ID: 3215280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of azaprophen, scopolamine and trihexyphenidyl on schedule-controlled behavior, before and after chronic physostigmine.
    Genovese RF
    Eur J Pharmacol; 1990 Feb; 176(3):271-9. PubMed ID: 2328755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mianserin as a discriminative stimulus in rats: asymmetrical cross-generalization with scopolamine.
    Kelley BM; Porter JH; Varvel SA
    Psychopharmacology (Berl); 1995 Aug; 120(4):491-3. PubMed ID: 8539332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of the behavioral effects of aprophen, atropine and scopolamine to antagonism of the behavioral effects of physostigmine.
    Genovese RF; Elsmore TF; Witkin JM
    Pharmacol Biochem Behav; 1990 Sep; 37(1):117-22. PubMed ID: 2263653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the discriminative stimulus effects of physostigmine in the rat.
    Locke KW; Gorney B; Cornfeldt M; Fielding S
    J Pharmacol Exp Ther; 1989 Jul; 250(1):241-6. PubMed ID: 2746500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discriminative stimulus properties of muscarinic agonists.
    Jung M; Costa L; Shearman GT; Kelly PH
    Psychopharmacology (Berl); 1987; 93(2):139-45. PubMed ID: 3122245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminative stimulus properties of the atypical antipsychotic drug clozapine in rats trained to discriminate 1.25 mg/kg clozapine vs. 5.0 mg/kg clozapine vs. vehicle.
    Prus AJ; Philibin SD; Pehrson AL; Porter JH
    Behav Pharmacol; 2006 Mar; 17(2):185-94. PubMed ID: 16495726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms.
    Prus AJ; Baker LE; Meltzer HY
    Pharmacol Biochem Behav; 2004 Feb; 77(2):199-208. PubMed ID: 14751446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discriminative stimulus properties of NIK-247 and tetrahydroaminoacridine, centrally active cholinesterase inhibitors, in rats.
    Yamamoto T; Ohno M; Sugimachi K; Ueki S
    Pharmacol Biochem Behav; 1993 Apr; 44(4):769-75. PubMed ID: 8469688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of oxotremorine-induced behavioral suppression by antimuscarinic drugs.
    Leander JD
    Psychopharmacology (Berl); 1981; 75(1):5-8. PubMed ID: 6795660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between scopolamine and muscarinic cholinergic agonists or cholinesterase inhibitors on spatial alternation performance in rats.
    Shannon HE; Bemis KG; Hendrix JC; Ward JS
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1071-7. PubMed ID: 2262893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discriminative stimulus properties of nicotine: further evidence for mediation at a cholinergic receptor.
    Pratt JA; Stolerman IP; Garcha HS; Giardini V; Feyerabend C
    Psychopharmacology (Berl); 1983; 81(1):54-60. PubMed ID: 6415731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.
    Shannon HE; Hart JC; Bymaster FP; Calligaro DO; DeLapp NW; Mitch CH; Ward JS; Fink-Jensen A; Sauerberg P; Jeppesen L; Sheardown MJ; Swedberg MD
    J Pharmacol Exp Ther; 1999 Aug; 290(2):901-7. PubMed ID: 10411607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intracerebroventricular pirenzepine on muscarinic discriminations in rats.
    Jung M; Perio A; Terranova JP; Worms P; Biziere K
    Eur J Pharmacol; 1987 Jul; 139(1):111-6. PubMed ID: 3653237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lead-induced changes in muscarinic cholinergic sensitivity.
    Cory-Slechta DA; Pokora MJ
    Neurotoxicology; 1995; 16(2):337-47. PubMed ID: 7566693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participation of the dorsal hippocampus in stimulus discrimination with scopolamine.
    Casasola C; Mejía-Gervacio S; Cruz-Pérez M; Sánchez-Castillo H; Velázquez-Martínez DN
    Brain Res; 2007 Oct; 1178():125-31. PubMed ID: 17927967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminative stimulus properties of arecoline: a new approach for studying central muscarinic receptors.
    Meltzer LT; Rosecrans JA
    Psychopharmacology (Berl); 1981; 75(4):383-7. PubMed ID: 6803285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.